UCB Gets EU Approval For Bimekizumab In Psoriasis

The European Commission has cleared UCB's UCBJF Bimzelx (bimekizumab) for moderate to severe plaque psoriasis in adults.
UCB's confidence lies in head-to-head studies that pitted Bimzelx against Novartis AG's NVS Cosentyx (secukinumab) and found that it was better at achieving complete clearance of skin lesions at both 16 and 48 weeks.
Bimekizumab is approved at a recommended dose of 320 mg, administered by two subcutaneous injections every four weeks to week 16 and every eight weeks after that.
Bimzelx has already been pre-approved for NHS reimbursement by NICE. Its costs are likely "similar or lower" than Cosentyx and other biologics used for psoriasis.
Related content: Benzinga's Full FDA Calendar
Price Action: UCBJF shares are up 9.07% at $114.95 during the market session on the last check Wednesday.